Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2018

Moore MD, Postma E, Gray KD, Ullmann TM, Hurley JR, Goldsmith S, et al. Less is More: The Impact of Multidisciplinary Thyroid Conference on the Treatment of Well-Differentiated Thyroid Carcinoma. World J Surg. 2018;42(2):343-349.

Han L, Zheng W, Zhai Y, Xie X, Zhang J, Zhang S, et al. Reference intervals of trimester-specific thyroid stimulating hormone and free thyroxine in Chinese women established by experimental and statistical methods. J Clin Lab Anal. 2018;32(4):e22344.

Bandini C, Pupuleku A, Spaccarotella E, Pellegrino E, Wang R, Vitale N, et al. IRF4 Mediates the Oncogenic Effects of STAT3 in Anaplastic Large Cell Lymphomas. Cancers (Basel). 2018;10(1).

Alperstein S, Dilcher T, Viswanathan K, Rao RA, Siddiqui MT, Giorgadze T. Acquired myospherulosis secondary to gluteal augmentation on fine needle aspiration cytology: A diagnostic challenge. Diagn Cytopathol. 2018;46(5):438-442.

Orleans RA, Magro CM, Varghese GI. A case of granuloma annulare mimicking tinea cruris. Dermatol Online J. 2018;24(8).

Chapman J, Geyer JT, Khanlari M, Moul A, Casas C, Connor ST, et al. Myeloid neoplasms with features intermediate between primary myelofibrosis and chronic myelomonocytic leukemia. Mod Pathol. 2018;31(3):429-441.

La Corte E, Younus I, Pivari F, Selimi A, Ottenhausen M, Forbes JA, et al. BRAF V600E mutant papillary craniopharyngiomas: a single-institutional case series. Pituitary. 2018;21(6):571-583.

Shoag J, Liu D, Blattner M, Sboner A, Park K, Deonarine L, et al. SPOP mutation drives prostate neoplasia without stabilizing oncogenic transcription factor ERG. J Clin Invest. 2018;128(1):381-386.

Lu X, Fernando TM, Lossos C, Yusufova N, Liu F, Fontan L, et al. PRMT5 interacts with the BCL6 oncoprotein and is required for germinal center formation and lymphoma cell survival. Blood. 2018;132(19):2026-2039.

Sowalsky AG, Ye H, Bhasin M, Van Allen EM, Loda M, Lis RT, et al. Neoadjuvant-Intensive Androgen Deprivation Therapy Selects for Prostate Tumor Foci with Diverse Subclonal Oncogenic Alterations. Cancer Res. 2018;78(16):4716-4730.